Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In this Viewpoint article, we asked three scientists working on the cancer mycobiome to provide their opinions on advancements and challenges and what the future holds for this exciting field of cancer research.
In their Review article, Fuchs and colleagues discuss how a single or a few mutations in adult cells can lead to invasive cancers without a high mutational burden, demonstrating that non-genetic factors induce the epigenetic changes necessary for tumorigenesis.
In this Tools of the Trade, Juliann Shih describes the development of BISCUT, which detects genomic loci that are subject to fitness advantages or disadvantages by interrogating the length distributions of partial somatic copy-number alterations to enable the discovery of new drivers of aneuploidy in cancer.
In this Viewpoint, we asked four experts to discuss the increasing burden of cancer in low- and middle-income countries; they explore the changes that are necessary to improve cancer diagnosis, prevention and treatment within these nations.
Mutant gain-of-function p53 is commonly found in human cancers. Huang, Cao, Qian et al. developed and validated the use of multifunctional biomimetic nanoreceptors that bind to and promote the degradation of mutant p53 as a cancer therapy.
In this Tools of the Trade article, Vakul Mohanty describes the development and use of METAFlux, a computational framework that infers metabolic flux from bulk and single-cell RNA-sequencing data.
In this Review, de Souza et al. discuss how advances in the ability to image protein markers at high-plex, at single-cell and even subcellular resolution, are expanding our understanding of tumour biology and clinical outcomes, and outline the future promise of combining such multiplex protein imaging methods with other forms of spatial omics.
Goddard et al. report that disseminated tumour cells evade T cell immunity due to their relative scarcity, which decreases the likelihood of T cell–tumour cell interactions.
Zhao et al. identified lymphatic endothelial-like cells in glioblastoma and demonstrated their role in promoting tumour growth through increased glioblastoma cholesterol metabolism.
Although p53 was once considered undruggable, in this Review, Peuget et al. discuss the progress made in targeting p53 as a form of cancer therapy with approaches ranging from restoration of mutant p53 function to inhibition of the negative regulator of p53, MDM2, as well as newer strategies, including p53-based mRNA vaccines and antibodies.
In this Perspective, Cambria et al. propose that mechanical cues within the primary tumour that are known to promote metastasis imprint a persistent phenotype on cancer cells through mechanical memory to further facilitate cancer metastasis at distant sites.
In this Journal Club, Góss dos Santos discusses a study that successfully generated sarcoma-derived organoids and utilized them to identify a novel therapeutic target.
Transposable elements, also known as junk DNA, constitute nearly half of the human genome. This Review by Liang et al. discusses how tumours exploit these transposable elements during their evolution but also how they represent a vulnerability that could be targeted through immunotherapeutic approaches.
In a recent Developmental Cell paper, Falvo et al. establish a role for epigenetic memory of inflammatory injury in promoting pancreatic tumorigenesis.
In a comprehensive study in acute myeloid leukaemia, Ozga et al. demonstrate sex-specific differences in the frequency and prognostic effect of genetic alterations.
Although hyperactivation of BRAF has been well-established to drive tumour progression and drug resistance, the role of CRAF in cancer is becoming increasingly relevant. Here, Riaud et al. summarize the various oncogenic roles of CRAF and the potential for CRAF-targeted therapies to improve the clinical outcome for RAF1 altered tumours.
In this Review, Sato and colleagues provide an overview of the clinicopathological and phenotypical impact of lineage commitment and plasticity during tumorigenesis and progression of human epithelial cancer and discuss the molecular mechanisms that underlie histological lineage transition.
Epidemiologic cohorts of cancer have contributed to the current understanding of cancer risk factors. In this Comment, Gomez and Cheng advocate for a new generation of cohorts that include underserved and understudied populations, and also address the roles of structural and social determinants of health.
